Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

@article{Fuchs2014RamucirumabMF,
  title={Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial},
  author={Charles S. Fuchs and Jiri Tomasek and Cho Jae Yong and Filip Dumitru and Rodolfo Passalacqua and Chanchal Goswami and Howard Safran and Lucas Vieira dos Santos and Giuseppe Aprile and David Raymond Ferry and Bohuslav Melichar and Mustapha Tehf{\'e} and Eldar E. Topuzov and John R. Zalcberg and Ian Chau and William Campbell and Choondal Sivanandan and Joanna Pikiel and Minori Koshiji and Yanzhi Hsu and Astra M Liepa and Ling Gao and Jonathan D. Schwartz and Josep M. Tabernero},
  journal={The Lancet},
  year={2014},
  volume={383},
  pages={31-39}
}

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

The addition of ramucirumab to front-line mFOLFOX6 did not improve PFS in the intent-to-treat (ITT) population, and an exploratory exposure-response analysis indicated that patients with higher ramucorumab exposure had longer OS.

Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study

It is suggested that ramucirumab monotherapy has clinical activity and a manageable safety profile in Japanese patients with gastric cancer after disease progression following first-line chemotherapy.
...

References

SHOWING 1-10 OF 29 REFERENCES

COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.

The primary endpoint was overall survival and patients were randomized to receive either docetaxel 75mg/m2every 3 weeks for up to 6 cycles or active symptom control (ASC), which could include any treatment thought by the treating clinician to be appropriate for the management of symptoms including radiotherapy, steroids and supportive medications.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  • A. OhtsuM. Shah Yoon-Koo Kang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Although AVAGAST did not reach its primary objective, adding bevacizumab to chemotherapy was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.

A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).

Addition of P to EOC chemotherapy was associated with worsening of OS in an unselected advanced OGA population, which may be in part due to lowered doses of O and C in the mEOC+P regimen.

Targeting angiogenesis in esophagogastric adenocarcinoma.

Evaluation of bevacizumab in the neoadjuvant and perioperative settings continues, hypothesizing that a higher response rate will translate into longer survival in patients with operable disease, and unable to personalize antiangiogenic therapy for established indications.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

  • J. SpratlinR. Cohen S. Eckhardt
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  • J. KangS. Lee S. Park
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
To the authors' knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC and in pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.

A systematic approach to therapeutic target selection in oesophago-gastric cancer

The MAPK pathway is commonly activated in oesophago-gastric cancer following activation of a variety of RTKs, and molecular phenotyping can inform a rational choice of targeted therapy.

Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.

Combined analysis of the VEGF-C/VEGF-D/VEGFR-3 system can be useful to identify patients with unfavorable clinical outcome and thereby may help to refine therapeutic decisions in gastric cancer.